U.S. Launch of Endologix VELA™ Proximal Endograft System

Aortic device specialist Endologix, Inc., is trumpeting the U.S. launch of its new VELA™ Proximal Endograft System which it says offers an attractive clinical solution for endovascular repair in a broad range of aortic neck anatomies.


Abdominal Aortic Aneurysms (AAA) are a leading cause of death in the United States. A weakening of the wall of the aorta results in a balloon-like enlargement which will progress and if left untreated becomes increasingly susceptible to rupture. Unsurprisingly, the overall patient mortality rate for ruptured AAA is approximately 75%.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders, specifically endovascular stent grafts for the treatment of AAAs.

The Endologix VELA stent graft system is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair (‘EVAR’) procedure using the Endologix AFX® Endovascular AAA System. Specifically it sits proximal to an already deployed AFX device, providing support for infrarenal AAAs.

Physician comments

One of the first VELA procedures in the United States was performed by Julio Rodriguez, M.D. FACS, a Vascular Surgeon at the Arizona Heart Institute. Dr. Rodriguez commented, “The VELA delivery system is very intuitive and the endograft has excellent visibility. Our early experience has been very positive and we are planning to use the VELA Proximal Endograft in a live EVAR procedure on February 12, 2014 at the iCON meeting in Phoenix, Arizona.” iCON is the International Congress on Endovascular Interventions, a well attended medical meeting for vascular specialists from around the world.

Company comments

“VELA is a next generation proximal endograft, designed based on our dedication to innovation leadership in AAA and feedback we collected from leading physicians,” said John McDermott, Chairman and CEO. “VELA’s new delivery system and unique circumferential graft line marker provide physicians with enhanced visibility and greater control over the implant procedure. We believe these enhancements lead to better precision and predictability of graft placement when coupled with our proprietary ActiveSeal™ technology. These features make VELA an attractive clinical solution for endovascular repair in a broad range of aortic neck anatomies.”

Source: Endologix, Inc., Globe Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *